Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + panobinostat
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of capecitabine, an oral prodrug of 5-fluorouracil that interferes with DNA synthesis, and panobinostat, a potent pan-histone deacetylase inhibitor that leads to hyperacetylation of histones and other intracellular proteins. This combination potentially offers synergistic anticancer effects as HDAC inhibition can increase thymidine phosphorylase expression, which is crucial for capecitabine's activation to its active form in tumor tissues.
02
Targets
HDAC (HDAC family)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + panobinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + panobinostat.